The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi (enzalutamide) or Janssen’s Zytiga ...
Data from the two Phase III trials showed that once-weekly insulin efsitora induced HbA1C reductions similar to daily insulin ...
The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
Eli Lilly announced positive results from two Phase III trials of once-weekly insulin efsitora alfa (efsitora) compared to daily insulin degludec for type 1 and type 2 diabetes. The trials, published ...
Eli Lilly LLY announced positive topline results from two phase III studies, QWINT-1 and QWINT-3, which evaluated efsitora alfa, its once-weekly administered investigational insulin, in adults with ...
The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...
Eli Lilly and Company has revealed positive topline results from the Phase III trials of efsitora alfa to treat adults with ...
Medpage Today on MSN6d
Lebrikizumab Wins FDA Approval for EczemaThe FDA approved lebrikizumab (Ebglyss) for treating atopic dermatitis in adults and children ages 12 years and up, drugmaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback